Vorapaxar

TypeName: Business Offer
Category:
Country: United States
Summary: SCH-530348 is a novel antiplatelet agent undergoing development by Schering-Plough Corp for the treatment and prevention of atherothrombosis. It is currently undergoing Phase-III clinical trials for acute coronary syndrome (unstable angina/non-ST segment elevation myocardial infarction) and secondary prevention of cardiovascular events in high-risk patients.
https://www.bocsci.com/vorapaxar-cas-618385-01-6-item-458444.html
Description: [RequestDescription]
OfferId: 2395
Name:Alex Brown
Telphone:
Categories